Navigation Links
DuPont to Acquire Danisco for $6.3 Billion
Date:1/9/2011

 10-Q, as well as others, could cause results to differ materially from those stated.  These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products; and severe weather events that cause business interruptions, including plant and power outages, or disruptions in supplier and customer operations. Risks and uncertainties relating to the acquisition that could cause the actual results to differ from expectations contemplated by forward looking statements include: uncertainties as to the timing of the tender offer; uncertainties as to how many of Danisco shareholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption from the transaction making it more difficult to maintain relationships with employees, customers, other business partners or governmental entities; if the tender offer is completed, failure to achieve the expected benefits of the proposed acquisition. The company undertakes no duty to update any forward-looking statements as a result of future developments or new information.


'/>"/>
SOURCE DuPont
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics
2. DuPont Leader: Global Demand for Renewable Innovations Growing
3. DuPont Named to Biofuels Digest 2010 “Transformative Technologies 303
4. DuPont Enhances its PROaccess℠ Business Strategy Through Acquisitions
5. Growing Demand for DuPont Renewable Products Drives Global Commercialization
6. DuPont Leader: Agricultural Improvements Key to Meeting Growing Food, Water Needs in Africa
7. DuPont to Expand Plant Genetics Research Facilities
8. U.S. Government Awards DuPont, Partners with Technology Investment Agreement for Macroalgae-to-Biobutanol Research
9. DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion
10. DuPont Leader: Drought-Tolerant Crops Developed Through Modern Breeding are Key to Sustainably Increasing Grain Production
11. DuPont Chair and CEO: Agriculture is Key to Global Economic Growth, Sustainability and Security
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ZIONA, Israel , September 2, ... TASE: BVXV) today announced the intent of the National Institute ... National Institutes of Health (NIH) within the Department of Health ... trial to be held in the United States ... the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to aid high-risk surgeries. From vital sign monitoring in ICU to 3D skull ... enables surgeon to make real-time clinical decisions with simultaneous access to high precision ...
(Date:9/2/2015)... ... September 02, 2015 , ... Temarry Recycling's new $100,000 waste ... energy process and continue to contribute to the sustainability of our natural resources. ... Energy process has been operating at their Mexico facility, Recicladora Temarry, for the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Genedata, a ... today unveiled Genedata Screener ® version 13.0 at ELRIG Drug Discovery 2015. ... market a rich set of new capabilities. Screener now supports High Throughput Flow ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... Inc. (Sparta),the maker of TrackWise(R), and the market ... that its TrackWise solution has,been chosen by Protherics ... manufacturing and marketing of specialized products for,critical care ... handling,processes. TrackWise provides organizations with a single, ...
... Oct. 24 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended,September ... on Thursday,November 1, 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) ... management and will be,held on Thursday, November 1, 2007, ...
... Call on Thursday, October 25, 2007 at ... ... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... the treatment of life-threatening,diseases, including diabetes and cancer, today announced its ...
Cached Biology Technology:Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 6
(Date:8/20/2015)... SANTA CLARA, Calif. , Aug. 20, 2015 ... based company focused on improving the user experience ... voice and vision technologies, today announced that its ... and voice biometric authentication software to be ... Alliance tested TrulySecure for compliance with the FIDO ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... 16, 2011 A new episode in the American ... podcast series spins a real-life tale in which spider ... the use of gene therapy in everyday medicine. ... explains in non-technical language that gene therapy involves the ...
... KAN. -- A Kansas State University research group is ... young children and prevent childhood obesity. The researchers ... head -- have developed a program called HOP,N Home, ... Nutrition at Home. The researchers have been working on ...
... headed by Prof. Johanna Ivaska (University of Turku and VTT ... of Turku and the National Institute for Health and Welfare) ... Published in a leading journal, the study concludes ... and of lung and prostate cancer cells. It is likely ...
Cached Biology News:New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy 2Research aims to prevent obesity by reaching parents, young children through child care 2Research aims to prevent obesity by reaching parents, young children through child care 3
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Phosphatidylinositol transfer protein beta isoform (PtdIns transfer protein beta) (PtdInsTP) (PI-TP-beta). [Source:Uniprot/SWISSPROT;Acc:P48739] Antigen: Recombinant Protein Epitope Signature Tag...
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Biology Products: